Biohaven's verdiperstat receives fast track designation for the treatment of multiple system atrophy

Biohaven Pharmaceutical

18 March 2020 - Biohaven Pharmaceutical announced today that the Company's myeloperoxidase inhibitor, verdiperstat, received Fast Track designation from the US FDA for the treatment of multiple system atrophy.

Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of myeloperoxidase, an enzyme that acts as a key driver of pathological oxidative stress and inflammation in the brain.

Read Biohaven Pharmaceutical press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track